Rygen Biopharma Profile
Key Indicators
- Authorised Capital ₹ 7.50 Cr
as on 13-12-2024
- Paid Up Capital ₹ 5.67 Cr
as on 13-12-2024
- Company Age 4 Year, 2 Days
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit -69.72%
(FY 2022)
- Ebitda -67.00%
(FY 2022)
- Net Worth -42.43%
(FY 2022)
- Total Assets 1.27%
(FY 2022)
About Rygen Biopharma
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 Cr and a paid-up capital of Rs 5.67 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vatti Reddy, Praneeth Vatti, Tulasiramu Chatadi, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24304TG2020PTC146965
- Company No.
146965
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2020
- Date of AGM
14 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rygen Biopharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vatti Reddy  | Managing Director | 06-Mar-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Praneeth Vatti | Additional Director | 06-Nov-2024 | Current |
| Tulasiramu Chatadi | Director | 17-Jan-2024 | Current |
| Venkata Dasari | Director | 17-Dec-2020 | Current |
| Vineeth Vatti | Additional Director | 06-Nov-2024 | Current |
Financial Performance and Corporate Structure Insights of Rygen Biopharma.
Rygen Biopharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 69.72% decrease in profit. The company's net worth observed a substantial decline by a decrease of 42.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rygen Biopharma?
Unlock access to Rygen Biopharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Genesys Biologics Private LimitedActive 10 years 1 monthTulasiramu Chatadi and Venkata Dasari are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rygen Biopharma?
Rygen Biopharma has a workforce of 0 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rygen Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rygen Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
